Kolexia
Brice Pauline Hématologie
Brice Pauline
Hématologie
Hôpital Saint-Louis
Paris, France
336 Activités
1 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Lymphomes Maladie de Hodgkin Lymphome folliculaire Lymphome T Récidive tumorale locale Lymphome malin non hodgkinien Lymphome T cutané Lymphome à grandes cellules anaplasiques Lymphome B

Collaborateurs

Voir plus
Casasnovas Rene-Olivier
Casasnovas Rene-Olivier
Hôpital François Mitterrand, Dijon, France
Salles Gilles
Salles Gilles
Hôpital Lyon Sud, Pierre-Bénite, France
Morschhauser Franck
Morschhauser Franck
Centre Hospitalier de Lille, Lille, France
Bouabdallah Reda
Bouabdallah Reda
Cabinet libéral, Aix-en-Provence, France

Industries

Voir plus
Takeda Pharmaceutical
19 collaboration(s)
Dernière en 2023
Amgen
3 collaboration(s)
Dernière en 2021
MSD
2 collaboration(s)
Dernière en 2021
Sandoz
1 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
RELEVANCE: A PHASE 3 OPEN-LABEL RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF RITUXIMAB PLUS LENALIDOMIDE (CC-5013) VERSUS RITUXIMAB PLUS CHEMOTHERAPY FOLLOWED BY RITUXIMAB IN SUBJECTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA The "RELEVANCE" Trial (Rituximab Lenalidomide Versus ANy ChEmotherapy)is Being Conducted as Two Companion Studies: RV-FOL-GELARC-0683 (N=750) and RV-FOL-GELARC-0683C (N=250); the Combined Total of 1000 Patients Enrolled in Both Studies Will be Analyzed.
Essai Clinique (Celgene)   13 mars 2024
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma: Prospective Controlled Trial in Clinical Stages I-II Supradiaphragmatic Hodgkin's Disease: Evaluation of Treatment Efficacy, (Long Term) Toxicity and Quality of Life in Two Different Prognostic Subgroups
Essai Clinique (Organisation européenne pour la recherche et le traitement du cancer)   21 février 2024
Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087): A Phase II Clinical Trial of MK-3475 (Pembrolizumab) in Subjects With Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL)
Essai Clinique (Merck & Co.)   12 janvier 2024
Allogreffe dans les lymphomes T cutanés avancés (CUTALLO) : une étude prospective contrôlée multicentrique, appariée par score de propension
Journées dermatologiques de Paris 2023   01 décembre 2023
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma: BEACOPP (4 Cycles Escalated + 4 Cycles Baseline) Versus ABVD (8 Cycles) In Stage III & IV Hodgkin's Lymphoma
Essai Clinique (Organisation européenne pour la recherche et le traitement du cancer)   08 novembre 2023
Combining PET/CT and Ctdna Assessments at 6 Months from Induction Treatment Better Predicts Outcome in Previously Untreated Patients with Follicular Lymphoma: A Relevance Ancillary Lysa Study
65th ASH Annual Meeting Abstracts   02 novembre 2023
Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group.
Blood advances   23 octobre 2023
Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up.
Blood advances   15 septembre 2023
Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma.
Blood   08 septembre 2023
RELEVANCE: A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Essai Clinique (Celgene)   10 août 2023